Skip to main
VALN
VALN

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE reported a strong financial performance for the full year 2024, achieving product sales of €163.3 million, reflecting a 13% year-over-year increase compared to €144.6 million in 2023. The company also disclosed total revenue of €169.6 million for 2024, marking a 10% rise from €153.7 million in the prior year, further underpinned by the recent FDA accelerated approval of its Ixchiq vaccine. With expectations of Ixchiq sales surpassing €100 million by the third year post-launch and a projected global market for chikungunya vaccines exceeding $500 million annually, Valneva's growth outlook appears robust, bolstered by its strategic focus on both marketed and developmental vaccine products.

Bears say

Valneva SE is projected to significantly reduce its operating cash burn from over €60.0 million in 2024 to less than €30 million in 2025, indicating a concerted effort to improve financial sustainability. The company's revenue forecast for 2025 has been diminished from €222.5 million to €185 million, which underscores declining sales expectations for its products, particularly Ixchiq. Additionally, the earnings per share (EPS) estimate for 2025 has been adjusted downward from (€0.53) to (€0.65), aligning with the reductions in revenue expectations and highlighting increasing concerns regarding the company’s profitability outlook.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.